TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be between 21 and 65 years old~* Must have an opiate dependence that meets criteria set in the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-V) Structured Clinical Interview for DSM (SCID-V) over the last three months~* No opioid use in the past 7 days (will be verified via urine drug screen and opiate metabolite test)~Exclusion Criteria:~* Using any psychoactive drug (other than nicotine) any time up to test session 3~* Having a diagnosis of drug dependence (except for heroin or nicotine) in the past 3 months, based on the SCID-V interview criteria~* Being maintained on methadone or buprenorphine, or taking opioid antagonists such as naltrexone~* Having a positive a drug screen~* Showing signs of acute heroin withdrawal symptoms~* Having medical conditions, including Axis I psychiatric conditions under DSM-V (examined using the Mini International Neuropsychiatric Interview \[MINI\])~* Having a a history of cardiac disease, arrhythmias, head trauma, and seizures~* Having a history of hypersensitivity to cannabinoids~* Arriving to the study site visibly intoxicated as determined by a clinical evaluation for signs and symptoms of intoxication and as verified by a drug screen~* Participating in a another pharmacotherapeutic trial in the past 3 months~* Being pregnant of breastfeeding~* Not using or irregularly using appropriate methods of contraception such as hormonal contraceptives (e.g., Depo-Provera, Nuva-Ring), an intrauterine device (IUD), or double barrier method (combination of any two barrier methods used simultaneously, e.g., condoms, spermicide, diaphragms)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Subjects will receive a solution that resemble the Cannabidiol solution but do not have have its properties
- CBD 400mg (Type: EXPERIMENTAL): Subjects will receive 400mg of cannabidiol
- CBD 800mg (Type: EXPERIMENTAL): Subjects will receive 800 mg of cannabidiol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who have had a diagnosis of type 2 diabetes mellitus for at least 6 months before screening~* Participants who have been taking sulfonylurea (glibenclamide, gliclazide, or glimepiride) and/or biguanide (metformin or buformin). The dose of the drug(s) during the 8 weeks before screening must be stable~* Participants who have a qualifying glycosylated hemoglobin (HbA1c) value of 7.0% to 10.0% at screening~* Participants who have a body mass index (BMI) of 18.5 to 35.0 kilograms per meter squared (kg/m\^2)~Exclusion Criteria:~* Participants who have a diagnosis of type 1 diabetes~* Participants who have previously been treated with any other glucagon-like peptide 1 (GLP-1) analog~* Participants who have received therapy with an alpha-glucosidase inhibitor (a-GI), thiazolidinedione (TZD), glinide, or dipeptidyl peptidase-IV (DPP-IV) inhibitor within 3 months before screening~* Participants who have been currently taking insulin or have had previous insulin treatment within 3 months before screening~* Participants who have obvious clinical signs or symptoms of pancreatitis, a history of chronic pancreatitis, or acute pancreatitis at screening, as determined by the investigator. Participants who have a serum amylase concentration ≥ 3 times the upper limit of the reference range and/or a serum lipase concentration ≥ 2 times the upper limit of the reference range, as determined by the central laboratory at screening~* Participants who have self or family history of medullary C-cell hyperplasia, focal hyperplasia, or medullary thyroid carcinoma (MTC)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY2189265 + OAM (Type: EXPERIMENTAL): LY2189265: 0.75 milligrams (mg), administered subcutaneously (SC), once weekly for 26 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin).
- Insulin glargine + OAM (Type: ACTIVE_COMPARATOR): Insulin glargine: dose based on targeting fasting blood glucose ≤110 milligrams per deciliter (mg/dL), administered subcutaneously (SC), once daily for 26 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Digital Interventions to Treat Hazardous Drinking

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Heavy or binge drinkers~* Either high or low COVID-19 related stress~Exclusion Criteria:~* Current or past substance use disorder other than mild alcohol, tobacco, marijuana use disorder~* Psychiatric disorders except for mood and anxiety disorders~* Any significant current medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Risky drinkers (Type: OTHER): All participants will receive the same 4-week intervention program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with Familial Mediterranean Fever according to Yalcinkaya or~* Tel-Hashomer criteria~* Diagnosis confirmed with the genetic analysis as compound heterozygote or~* homozygote mutation~* Patients between ages of 5-16 and weighted 15-30 kg~* Not received any treatment for FMF~Exclusion criteria:~* Major congenital malformation~* Organ transplantation~* Hepatic disorder~* Chronic kidney disease~* AA amyloidosis~* Thyroid disease~* Rheumatologic disorders other than FMF

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- once daily dosage schema of colchicine (Type: EXPERIMENTAL): The once daily dosage group was prescribed as once daily at 08:00 a.m. (Total 1mg)
- twice daily dosage schema of colchicine (Type: EXPERIMENTAL): Twice daily dosage group received the treatment twice daily at 08:00 a.m. and 08:00 p.m. (Total 1mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~primary or sec. kidney transplanted patiens, written consent, cold ischemia \< 24 h~Exclusion:~multi organ, immunological risc pts., PRA \>20%, Antibodys against HLA-type of donor organ, hypersensitivity against Tacro or MMF,~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Prograf (Type: EXPERIMENTAL): Control therapy: one capsule containing 0.5 mg, 1mg or 5mg Prograf®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®
- Tacroliums Hexal (Type: EXPERIMENTAL): Investigational therapy: one capsule containing 0.5mg, 1mg or 5mg Tacrolimus Hexal®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically documented Stage IB, II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion) NSCLC~* Adequate pulmonary and cardiac function~* Available biopsy of primary tumor with adequate samples~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Exclusion Criteria:~* NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by virtue of N3 disease~* Any prior therapy for lung cancer within 3 years.~* Prior treatment with anti-PD-1 or PD-L1 therapies~* History or risk of autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atezolizumab (Type: EXPERIMENTAL): Participants received two cycles of atezolizumab as neoadjuvant therapy prior to surgery. Participants who demonstrated clinical benefit were eligible to receive up to 12 months of atezolizumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* normal renal function or renal impairment~* stable hemodialysis treatment for at least 3 months before screening and able to tolerate a hemodialysis treatment lasting 3-4 hours with blood flow rates of \>200mL/min (cohort 3 only)~* neither pregnant nor lactating~* HbA1c 6-10.5% inclusive~* females of childbearing potential must be practicing adequate contraception.~Exclusion Criteria:~* inability to meet the PK objectives of the study~* history of hypoglycemia unawareness or severe hypoglycemia~* liver function tests greater than or equal to 2 times the ULN~* clinically significant cardiovascular and/or cerebrovascular disease~* positive test results for hepatitis B, hepatitis C, or HIV~* documented hypertension or hypotension at screening~* known hepatic or biliary abnormalities~* current use of sulfonylureas~* active history of tobacco use within 6 months before screening~* donation of blood in excess of 500mL within 56 days before albiglutide dosing~* receipt of any investigational drug within the 30days or 5 half lives, whichever is longer, before dosing~* previous or current receipt of exenatide or any other GLP-1 agonist

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Stage 1 normal renal function (Type: EXPERIMENTAL): Subject with estimated glomerular filtration rate (GFR) greater than 80 milliliter per minute (mL/min)
- Stage 1 moderate/severe renal function (Type: EXPERIMENTAL): Subject with estimated GFR \>= 20 mL/min and less than 50 mL/min
- Stage 2 normal renal function (Type: EXPERIMENTAL): Subject with GFR greater than 80 mL/min
- Stage 2 moderate renal impairment (Type: EXPERIMENTAL): Subject with estimated GFR \>= 30 mL/min and less than 50 mL/min
- Stage 2 subjects requiring hemodialysis (Type: EXPERIMENTAL): Subjects who require hemodialysis
- Stage 2 severe renal impairment not requiring hemodialysis (Type: EXPERIMENTAL): Subjects with GFR less than 30 mL/min
- Stage 2 mild renal impairment (Type: EXPERIMENTAL): Subjects with GFR \>= 50 mL/min and \<= 80 mL/min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy female subjects of non-childbearing potential and healthy male subjects~* Have a body weight between 60.0 and 94.9 kg and a body mass index between 20.0 and 29.9 kg/m², inclusive.~Exclusion Criteria:~* history and/or current presence of clinical significant atopic allergy, hypersensitivity or allergic reactions, also including known or suspected clinically relevant drug hypersensitivity to any components of the test and reference IP formulation or comparable drugs.~* active or latent Tuberculosis or who have a history of Tuberculosis.~* history of invasive systemic fungal infections or other opportunistic infections~* systemic or local infection, a known risk for developing sepsis and/or known active inflammatory process~* serious infection associated with hospitalisation and/or which required intravenous antibiotics~* history of and/or current cardiac disease~* have received live vaccine(s) within 30 days prior to Screening or who will require live vaccine(s) between Screening and the final study visit.~* Intake medication with a half-life \> 24 h within 1 month or 10 half-lives of the medication prior to the administration of investigational product.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- SB2 (Type: EXPERIMENTAL): SB2 (Study drug)
- EU Remicade (Type: ACTIVE_COMPARATOR): EU sourced Remicade (Reference drug)
- US Remicade (Type: ACTIVE_COMPARATOR): US sourced Remicade (Reference drug)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible participants included patients ≥20 years who had undergone gastroscopy for melena, haematochezia, or haematemesis due to bleeding peptic ulcers with major stigmata of recent hemorrhage. The major stigmata of recent haemorrhage were classified as Forrest class Ia, Ib, IIa, and IIb. All of the stigmata are given one or a combination of endoscopic therapies, including local injection of diluted epinephrine 1:10000, bipolar heated probe, argon plasma coagulation, band ligation, or hemoclip therapy. Patients will undergo a follow-up endoscopy about 12 to 16 weeks later to confirm that the ulcer has healed to be less than 0.5 cm; otherwise, patients are not enrolled.~Exclusion Criteria:~* Patients are excluded if they had tumor bleeding or ulcer bleeding due to the presence of a Dieulafoy lesion or mechanical factors (e.g, gastrostomy tube induction), comorbid with reflux esophagitis grade C or D, Barrett's esophagus, or marginal ulcer bleeding, hypersensitivity to esomeprazole or any component of the formulation, or had previously participated in the study. Because of concern for patient safety with certain drug-drug interactions, patients who receive anti-platelet therapy, e.g., aspirin, clopidogrel, or others for prophylaxis of established cardiovascular or cerebrovascular diseases will be excluded.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- The D group (Type: EXPERIMENTAL): After 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment, patients receive oral esomeprazole 20 mg twice daily for 36 weeks.
- The S group (Type: EXPERIMENTAL): After 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment, patients receive oral esomeprazole 20 mg once daily for 36 weeks.
- The C group (Type: NO_INTERVENTION): The cohort control group includes patients from a previous study who had peptic ulcer bleeding and Rockall scores ≥ 6 but who did not receive esomeprazole or other proton pump inhibitors after 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ice Immersion Using Virtual Reality & Augmented Reality

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than 18 years of age~* English speaking~* Hearing intact~Exclusion Criteria:~* Patients who do not consent~* Currently taking beta blockers or other chronotropic heart medication(s)~* Have a history of severe motion sickness~* Currently have nausea~* Currently experiencing seizures~* Are clinically unstable~* Have taken pain medications in the last 12 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ice bath Control then VR/AR (Type: EXPERIMENTAL): Participants will be randomized with a 1:1 allocation to use their dominant or non-dominant hand with VR or control (no VR) for the cold pressor test and then crossed over. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
- Ice bath with VR/AR then Control (Type: EXPERIMENTAL): Participants will be randomized with a 1:1 allocation to use their dominant or non-dominant hand with VR or control (no VR) for the cold pressor test and then crossed over. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years at diagnosis~* Diagnosed with ATTRv-CM, mixed phenotype~* Treated with tafamidis (VYNDAQEL 80 mg \[four 20-mg tafamidis meglumine capsules\] orally once daily or VYNDAMAX 61 mg \[one 61-mg tafamidis capsule\] orally once daily) for ≥6 months~* Have had ≥1 pre- and ≥2 post-treatment neurologic assessments~Exclusion Criteria:~* History of organ transplant~* Wild-type TTR genotype~* Individuals who are non-ambulatory~* Prior treatment with any disease-modifying therapy (investigational or approved) alone or in combination, except tafamidis, as either VYNDAQEL 80 mg (four 20-mg tafamidis meglumine capsules) orally once daily or VYNDAMAX 61 mg (one 61-mg tafamidis capsule) orally once daily~* Peripheral neuropathy attributed to causes other than ATTR amyloidosis (e.g., diabetes mellitus, B12 deficiency, HIV infection)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with mixed phenotype ATTRv-CM (Type: None): Hereditary ATTR-CM patients presenting with mixed phenotype

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Modulation of Cerebral Blood Flow Using Iron Chelators

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy adults between the ages of 18-80 years.~Exclusion Criteria:~* subjects taking vasoactive medications,~* hypertension,~* pregnant women, smokers,~* COPD,~* asthma,~* diabetes mellitus,~* intracranial or carotid stenosis,~* hepatic disease,~* renal disease,~* bone marrow suppression,~* cardiac disease,~* heart failure,~* iron deficiency,~* history of cancer,~* history of head trauma,~* subarachnoid hemorrhage,~* central nervous system vasculitis,~* multiple sclerosis,~* migraines,~* seizures,~* sickle cell disease or trait,~* cardiac arrhythmia,~* unable to give informed consent, or~* poor transcranial Doppler insonation windows.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Healthy young (Type: EXPERIMENTAL): Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.
- healthy old (Type: EXPERIMENTAL): Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete